Catecholamine prodrugs for use in the treatment of parkinson’s disease
US-2025381208-A1 · Dec 18, 2025 · US
This page is not indexed by search engines while we improve data quality.
Acyclic radicals, not substituted by cyclic structures
Acyclic radicals, not substituted by cyclic structures · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07H15/02 |
| Official title | Acyclic radicals, not substituted by cyclic structures |
| Display label | Acyclic radicals, not substituted by cyclic structures |
| Total patents | 21 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 3 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Mimetics of heparin oligosaccharides
US-12378278-B2 · Aug 5, 2025 · US
Catecholamine prodrugs for use in the treatment of Parkinson's disease
US-12226428-B2 · Feb 18, 2025 · US
Catecholamine prodrugs for use in the treatment of parkinson’s disease
US-2024156851-A1 · May 16, 2024 · US
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US-11827665-B2 · Nov 28, 2023 · US
Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
US-11773129-B2 · Oct 3, 2023 · US
New glycolipids and use thereof as sk3 ion channel modulators
US-2023287031-A1 · Sep 14, 2023 · US
Catecholamine prodrugs for use in the treatment of parkinson's disease
US-11707476-B2 · Jul 25, 2023 · US
Novel mimetics of heparin oligosaccharides
US-2023012702-A1 · Jan 19, 2023 · US
New catecholamine prodrugs for use in the treatment of parkinson's disease
US-2022257623-A1 · Aug 18, 2022 · US
Process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US-2022185839-A1 · Jun 16, 2022 · US
Catecholamine prodrugs for use in the treatment of Parkinson's disease
US-11110110-B2 · Sep 7, 2021 · US
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US-11104697-B2 · Aug 31, 2021 · US
A process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US-2020369705-A1 · Nov 26, 2020 · US
Catecholamine prodrugs for use in the treatment of parkinson's disease
US-2020338102-A1 · Oct 29, 2020 · US
Catecholamine prodrugs for use in the treatment of Parkinson's disease
US-10729710-B2 · Aug 4, 2020 · US
Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
US-2020239512-A1 · Jul 30, 2020 · US
Catecholamine prodrugs for use in the treatment of parkinson's disease
US-2019160083-A1 · May 30, 2019 · US
Vaccines against Streptococcus pneumoniae serotype 4
US-10188718-B2 · Jan 29, 2019 · US
Compounds and methods for targeted immune system delivery
US-9962448-B2 · May 8, 2018 · US